Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 51,240 | 44,206 | 38,285 | 32,061 | 26,425 |
| Cost of Goods | 298 | 238 | 382 | 177 | 136 |
| Gross Profit | 50,942 | 43,968 | 37,903 | 31,884 | 26,289 |
| Operating Expenses | 112,937 | 113,997 | 102,968 | 87,691 | 97,710 |
| Operating Income | -61,697 | -69,791 | -64,683 | -55,630 | -71,285 |
| Interest Expense | 31,244 | 26,150 | 28,079 | 27,584 | 28,884 |
| Other Income | -137,449 | -536,847 | 30,669 | 15,905 | 7,864 |
| Pre-tax Income | -230,390 | -632,788 | -62,093 | -67,309 | -92,305 |
| Income Tax | N/A | 9 | -135 | -35 | 269 |
| Net Income Continuous | -230,390 | -632,797 | -61,958 | -67,274 | -92,574 |
| Minority Interests | -12 | -15 | -14 | -21 | -19 |
| Net Income | $-230,378 | $-632,782 | $-61,944 | $-67,253 | $-92,555 |
| EPS Basic Total Ops | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 |
| EPS Basic Continuous Ops | -0.22 | -0.62 | -0.05 | -0.07 | -0.10 |
| EPS Diluted Total Ops | -0.22 | -0.62 | -0.06 | -0.07 | -0.10 |
| EPS Diluted Continuous Ops | -0.22 | -0.62 | -0.05 | -0.07 | -0.10 |
| EPS Diluted Before Non-Recurring Items | -0.08 | -0.09 | -0.06 | -0.07 | -0.10 |
| EBITDA(a) | $-55,764 | $-66,937 | $-60,818 | $-51,679 | $-67,353 |